BioCentury | Aug 19, 2020
Management Tracks

Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more

...NASDAQ:BCYC) as CMO. Blanc was the founder and medical director of Phi-Medics, a clinical development consultancy.StrideBio Inc....
...where he was EVP of technical operations. Robin Sawka Swedish Orphan Biovitrum AB Ikena Oncology Agile Therapeutics Inc. Nordic Nanovector ASA StrideBio Inc....
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...small molecule cancer therapies (see "Cybrexa: pH-Based Tumor Targeting" ). Adeno-associated viral-based gene therapy company StrideBio Inc....
...S.A. Cybrexa Therapeutics Inc. Owlstone Medical Ltd. PCI Biotech Holding ASA CureVac AG Pfizer Inc. Oric Pharmaceuticals Inc. Kyowa Hakko Kirin Co. Ltd. StrideBio Inc. BioCryst...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...“Taking Gene Therapy to the Next Level”). Biotechs engineering the capsid of viral vectors include StrideBio Inc....
...the capsid can modify the cell surface proteins and prevent their interaction with immune cells. StrideBio...
BioCentury | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

...that can evade neutralizing antibodies (see “AAV Plasmid Company StrideBio Raises $15.7M Series A” ). StrideBio...
...also gained the option to exclusively license StrideBio’s technology for four more programs. If exercised, StrideBio...
...partner with StrideBio across three deals. CRISPR Therapeutics AG (NASDAQ:CRSP) and Casebia Therapeutics exclusively licensed StrideBio’s...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...acquired TAK-754 (formerly SHP654) to treat hemophilia A, plus undisclosed preclinical AAV vectors N/A 1/8/2019 StrideBio Inc....
...it partnered with StrideBio to develop novel AAV capsids for neurological diseases including Friedreich's Ataxia. StrideBio...
...Templates Inc. (NASDAQ:MTEM), Austin, Texas Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland NsGene A/S, Ballerup, Denmark StrideBio Inc....
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...company StrideBio Inc. (Durham, N.C.) hired Sapan Shah as its first CEO. Shah, who also joined StrideBio's...
BioCentury | Jun 22, 2018
Finance

Direct from UCB Ventures

...UCB Ventures’ recent investment in Durham, N.C.-based gene therapy play StrideBio Inc. marks the next phase in...
...in other neurodegenerative diseases, neuroinflammation or Orphan CNS disorders, Whittaker said. The fund’s investment in StrideBio’s...
...its first -- is illustrative of how UCB Ventures aims to deploy the funds. StrideBio...
BioCentury | Jun 15, 2018
Financial News

AAV plasmid company StrideBio raises $15.7M series A

...Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio...
...BioCentury the round gives the adeno-associated viral vector plasmid company a cash runway into 2019. StrideBio...
...direct investment. StrideBio Inc., Durham, N.C. Jaime De Leon Alexandria Venture Investments Bayer AG CRISPR Therapeutics AG Takeda Ventures CRISPR-associated protein 9 (Cas9) StrideBio Inc....
BioCentury | Jun 13, 2018
Financial News

AAV plasmid company StrideBio raises $15.7M series A

...Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio...
...BioCentury the round gives the adeno-associated viral vector plasmid company a cash runway into 2019. StrideBio...
...and capacity for manufacture. The company plans to focus on treating rare diseases. In 2017, StrideBio...
BioCentury | Nov 2, 2017
Emerging Company Profile

Tougher Tregs

...Seattle Children’s Research Institute Corporate partners: Bayer AG, CRISPR Therapeutics AG, MaxCyte Inc. , StrideBio...
Items per page:
1 - 10 of 12
BioCentury | Aug 19, 2020
Management Tracks

Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more

...NASDAQ:BCYC) as CMO. Blanc was the founder and medical director of Phi-Medics, a clinical development consultancy.StrideBio Inc....
...where he was EVP of technical operations. Robin Sawka Swedish Orphan Biovitrum AB Ikena Oncology Agile Therapeutics Inc. Nordic Nanovector ASA StrideBio Inc....
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...small molecule cancer therapies (see "Cybrexa: pH-Based Tumor Targeting" ). Adeno-associated viral-based gene therapy company StrideBio Inc....
...S.A. Cybrexa Therapeutics Inc. Owlstone Medical Ltd. PCI Biotech Holding ASA CureVac AG Pfizer Inc. Oric Pharmaceuticals Inc. Kyowa Hakko Kirin Co. Ltd. StrideBio Inc. BioCryst...
BioCentury | Jan 18, 2020
Product Development

Mapping the path to gene therapy 2.0

...“Taking Gene Therapy to the Next Level”). Biotechs engineering the capsid of viral vectors include StrideBio Inc....
...the capsid can modify the cell surface proteins and prevent their interaction with immune cells. StrideBio...
BioCentury | Nov 15, 2019
Company News

Sarepta partners with StrideBio to enable viral gene therapy re-dosing

...that can evade neutralizing antibodies (see “AAV Plasmid Company StrideBio Raises $15.7M Series A” ). StrideBio...
...also gained the option to exclusively license StrideBio’s technology for four more programs. If exercised, StrideBio...
...partner with StrideBio across three deals. CRISPR Therapeutics AG (NASDAQ:CRSP) and Casebia Therapeutics exclusively licensed StrideBio’s...
BioCentury | Jul 26, 2019
Product Development

Takeda's deals paint a picture of a turnaround in action

...acquired TAK-754 (formerly SHP654) to treat hemophilia A, plus undisclosed preclinical AAV vectors N/A 1/8/2019 StrideBio Inc....
...it partnered with StrideBio to develop novel AAV capsids for neurological diseases including Friedreich's Ataxia. StrideBio...
...Templates Inc. (NASDAQ:MTEM), Austin, Texas Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland NsGene A/S, Ballerup, Denmark StrideBio Inc....
BioCentury | Jan 5, 2019
Company News

Flurry of management moves on eve of JPM

...company StrideBio Inc. (Durham, N.C.) hired Sapan Shah as its first CEO. Shah, who also joined StrideBio's...
BioCentury | Jun 22, 2018
Finance

Direct from UCB Ventures

...UCB Ventures’ recent investment in Durham, N.C.-based gene therapy play StrideBio Inc. marks the next phase in...
...in other neurodegenerative diseases, neuroinflammation or Orphan CNS disorders, Whittaker said. The fund’s investment in StrideBio’s...
...its first -- is illustrative of how UCB Ventures aims to deploy the funds. StrideBio...
BioCentury | Jun 15, 2018
Financial News

AAV plasmid company StrideBio raises $15.7M series A

...Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio...
...BioCentury the round gives the adeno-associated viral vector plasmid company a cash runway into 2019. StrideBio...
...direct investment. StrideBio Inc., Durham, N.C. Jaime De Leon Alexandria Venture Investments Bayer AG CRISPR Therapeutics AG Takeda Ventures CRISPR-associated protein 9 (Cas9) StrideBio Inc....
BioCentury | Jun 13, 2018
Financial News

AAV plasmid company StrideBio raises $15.7M series A

...Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio...
...BioCentury the round gives the adeno-associated viral vector plasmid company a cash runway into 2019. StrideBio...
...and capacity for manufacture. The company plans to focus on treating rare diseases. In 2017, StrideBio...
BioCentury | Nov 2, 2017
Emerging Company Profile

Tougher Tregs

...Seattle Children’s Research Institute Corporate partners: Bayer AG, CRISPR Therapeutics AG, MaxCyte Inc. , StrideBio...
Items per page:
1 - 10 of 12